May 28, 2025
Investors of drugmaker Mallinckrodt received preliminary approval of their $5.5 million settlement with two executives and a director of the company Wednesday, ending the investors' claims they were misled into believing Mallinckrodt had recovered from bankruptcy and would make a $200 million payment to opioid claimants.
September 23, 2024
A New Jersey federal judge ruled Monday that senior leaders of drugmaker Mallinckrodt cannot escape a lawsuit brought by shareholders alleging the company tricked them into thinking it had recovered from bankruptcy and would make a $200 million payment to opioid claimants, finding the investors sufficiently pleaded securities law violations.
September 21, 2023
Pomerantz LLP has been appointed lead counsel in a suit asserting insolvent drugmaker Mallinckrodt PLC tricked investors into thinking it had recovered from bankruptcy and would make a $200 million payment to an opioid fund, a New Jersey federal judge said in an order.
September 06, 2023
Two corporate investors have asked a New Jersey federal judge to name Pomerantz LLP as lead counsel in their suit accusing Mallinckrodt PLC of deceiving shareholders into believing the drugmaker had bounced back from bankruptcy and would be able to pay $200 million to an opioid fund.
July 10, 2023
Drugmaker Mallinckrodt PLC deceived shareholders that it had bounced back from bankruptcy and would be able to pay $200 million to an opioid fund, according to a proposed class action filed after the company announced that it is considering filing for Chapter 11 for a second time.